Oxytocic Pharmaceuticals Market to worth US$ 157.6 million by 2026 End

Europe Hospital Capacity Management Solutions Market
Synthetic Oxytocic Pharmaceuticals will Amass Nearly US$ 150 Million Revenues by 2026-end
Though synthetic oxytocin is chemically equivalent to naturally-occurring oxytocin, their pharmaceutical
functions for aiding women in labour are quite distinctive. Medical professionals from around the world
will continue to recommend synthetic-based oxytocic pharmaceuticals over natural since oxytocic
pharmaceuticals originating from synthetic sources can boost the momentum of decelerated labour by IV
administration. More than 90% of the global market revenues for oxytocic pharmaceuticals will be
harvested from the sales of oxytocic pharmaceuticals originating from synthetic sources. By the end of
2026, an estimated US$ 148.9 million revenues will be emanated from the global sales of synthetic
oxytocic pharmaceuticals.
Future Market Insights’ published report on the global oxytocic pharmaceuticals market estimates that
the market, which is presently valued at US$ 62.2 million, will expand at an impressive 9.7% CAGR to
reach US$ 157.6 million value by 2026-end. In the report, titled “Oxytocic Pharmaceuticals Market:
Global Industry Analysis & Opportunity Assessment, 2016-2026,” Future Market Insights projects that
the global market for oxytocic pharmaceuticals will remain highly fragmented due to higher prevalence of
local players as opposed to multinationals and conglomerates. Nevertheless, global pharmaceutical
industry leaders such as Pfizer Inc., Novartis AG, Baxter Healthcare Corporation, and Teva Pharmaceutical
Industries Ltd. are also partaking in the global oxytocic pharmaceuticals market. Other leading
manufacturers of oxytocic pharmaceuticals include Biofutura Pharma SpA, Ferring BV, and Fresenius Kabi
AG.
©2015 Future Market Insights, All Rights Reserved 4